Observational studyBreast cancer (Tokyo, Japan)2022

Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial.

Hitoshi Tsuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.